CancerDrs

Breast Cancer clinical trials in Colorado

40 actively recruiting breast cancer trials at 27 sites across Colorado.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full breast cancer transparency page →

Phase 3 Recruiting Academic/Other

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…

Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Colorado:
  • UCHealth University of Colorado Hospital — Aurora, Colorado
  • Penrose-Saint Francis Healthcare — Colorado Springs, Colorado
  • Rocky Mountain Cancer Centers-Penrose — Colorado Springs, Colorado
  • UCHealth Memorial Hospital Central — Colorado Springs, Colorado
  • Memorial Hospital North — Colorado Springs, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Colorado:
  • Rocky Mountain Cancer Centers-Aurora — Aurora, Colorado
  • Boulder Community Foothills Hospital — Boulder, Colorado
  • Rocky Mountain Cancer Centers-Boulder — Boulder, Colorado
  • Intermountain Health Platte Valley Hospital — Brighton, Colorado
  • Rocky Mountain Cancer Centers - Centennial — Centennial, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 nega…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06058377
Sites in Colorado:
  • UCHealth University of Colorado Hospital — Aurora, Colorado
  • UCHealth - Cherry Creek — Denver, Colorado
  • Shaw Cancer Center — Edwards, Colorado
  • Poudre Valley Hospital — Fort Collins, Colorado
  • Cancer Care and Hematology-Fort Collins — Fort Collins, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…

Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in Colorado:
  • University of Colorado Cancer Center — Aurora, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed def…

Sponsor: AstraZeneca
NCT ID: NCT05774951
Sites in Colorado:
  • Research Site — Aurora, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positi…

Sponsor: Pfizer
NCT ID: NCT07062965
Sites in Colorado:
  • Rocky Mountain Cancer Centers LLP — Aurora, Colorado
  • Rocky Mountain Cancer Centers LLP — Boulder, Colorado
  • Rocky Mountain Cancer Centers LLP — Centennial, Colorado
  • Rocky Mountain Cancer Centers LLP — Colorado Springs, Colorado
  • Rocky Mountain Cancer Centers LLP — Colorado Springs, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 60 years) tolerate side effects and stay on treatment longer, to der…

Sponsor: American Society of Clinical Oncology
NCT ID: NCT06377852
Sites in Colorado:
  • University of Colorado Anschutz Medical Campus — Aurora, Colorado
  • UCHealth Cherry Creek Medical Center — Denver, Colorado
  • UCHealth Highlands Ranch Hospital — Highlands Ranch, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…

Sponsor: AstraZeneca
NCT ID: NCT06103864
Sites in Colorado:
  • Research Site — Aurora, Colorado
  • Research Site — Denver, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in th…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06966700
Sites in Colorado:
  • Intermountain Health Cancer Center Saint Joseph ( Site 0062) — Denver, Colorado
  • Rocky Mountain Cancer Centers (RMCC) ( Site 8006) — Denver, Colorado
  • Intermountain Health St. Mary's Regional Hospital ( Site 0054) — Grand Junction, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.

Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT07085767
Sites in Colorado:
  • Clinical Trial Site — Aurora, Colorado
  • Clinical Trial Site — Denver, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+,…

Sponsor: AstraZeneca
NCT ID: NCT06380751
Sites in Colorado:
  • Research Site — Aurora, Colorado
  • Research Site — Grand Junction, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutati…

Sponsor: Relay Therapeutics, Inc.
NCT ID: NCT06982521
Sites in Colorado:
  • Rocky Mountain Cancer Centers, LLP — Longmont, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have complete…

Sponsor: Greenwich LifeSciences, Inc.
NCT ID: NCT05232916
Sites in Colorado:
  • Rocky Mountain Cancer Centers — Denver, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metasta…

Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06435429
Sites in Colorado:
  • University of Colorado-Cancer Center-PPDS — Aurora, Colorado
  • Rocky Mountain Cancer Centers — Denver, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth fa…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06312176
Sites in Colorado:
  • University of Colorado Anschutz Medical Campus ( Site 0061) — Aurora, Colorado
  • UCHealth Cherry Creek Medical Center ( Site 0094) — Denver, Colorado
  • University of Colorado Health - Highlands Ranch Hospital ( Site 0095) — Highlands Ranch, Colorado
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-pa…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT06926868
Sites in Colorado:
  • Local Institution - 0289 — Aurora, Colorado
  • Rocky Mountain Cancer Centers — Denver, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. * HR positive (H…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07060807
Sites in Colorado:
  • St. Marys Hospital and Regional Medical Center-SCL Health Cancer Centers of Colorado ( Site 0021) — Grand Junction, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib and palbociclib plus endocrine therapy for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast …

Sponsor: Celcuity Inc
NCT ID: NCT06757634
Sites in Colorado:
  • University of Colorado Hospital - Cancer Center — Aurora, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy

In the setting of radiotherapy as part of breast-conservation therapy for patients with early stage breast cancer, the novel planning and delivery method of intensity modulated radiotherapy is an effective and safe alternative to the commo…

Sponsor: Rocky Mountain Cancer Centers
NCT ID: NCT01185132
Sites in Colorado:
  • Rocky Mountain Cancer Centers - Aurora — Aurora, Colorado
  • Rocky Mountain Cancer Centers - Boulder — Boulder, Colorado
  • Rocky Mountain Cancer Centers - Lakewood — Lakewood, Colorado
  • Rocky Mountain Cancer Centers - Littleton — Littleton, Colorado
  • Rocky Mountain Cancer Centers - Thornton — Thornton, Colorado
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Colorado:
  • UCHealth University of Colorado Hospital — Aurora, Colorado
  • Poudre Valley Hospital — Fort Collins, Colorado
  • Cancer Care and Hematology-Fort Collins — Fort Collins, Colorado
  • UCHealth Greeley Hospital — Greeley, Colorado
  • Medical Center of the Rockies — Loveland, Colorado
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

This study will include two groups of patients: Cohort 1 and Cohort 2. Cohort 1: will help researchers learn how a medicine called imlunestrant (LY3484356) affects a specific type of breast cancer. Some patients will take both imlunestrant…

Sponsor: Eli Lilly and Company
NCT ID: NCT07287098
Sites in Colorado:
  • Banner MD Anderson Cancer Center at North Colorado Medical Center — Greeley, Colorado
  • Banner MD Anderson Cancer Center at McKee Medical Center — Loveland, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

This study will evaluate the safety, tolerability, and preliminary effectiveness of AMXT 1501 and DFMO when combined with standard treatments for advanced solid tumors. The trial includes two groups: * Cohort 1: Patients with ER+ / HER2- b…

Sponsor: Aminex Therapeutics, Inc.
NCT ID: NCT07287917
Sites in Colorado:
  • Skin Cancer Institute — Englewood, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295…

Sponsor: Accent Therapeutics
NCT ID: NCT06799065
Sites in Colorado:
  • University of Colorado Denver — Aurora, Colorado
View on ClinicalTrials.gov →

Showing 25 of 40 trials with sites in Colorado. See all breast cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-12